Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair | Zendy

XiPing Huang | Zendy; Zhuo Sun | Zendy; Yasuo Miyagi | Zendy; Heather McDonald Kinkaid | Zendy; Li Zhang | Zendy; Richard D. Weisel | Zendy; RenKe Li | Zendy

Open Access

Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair

Author(s) -

XiPing Huang,

Zhuo Sun,

Yasuo Miyagi,

Heather McDonald Kinkaid,

Li Zhang,

Richard D. Weisel,

RenKe Li

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.955971

Subject(s) - mesenchymal stem cell , medicine , stem cell , immune system , immunology , immunogenicity , cell therapy , myocardial infarction , transplantation , in vivo , bone marrow , cardiac function curve , cancer research , heart failure , pathology , biology , microbiology and biotechnology

Cardiac cell therapy for older patients who experience a myocardial infarction may require highly regenerative cells from young, healthy (allogeneic) donors. Bone marrow mesenchymal stem cells (MSCs) are currently under clinical investigation because they can induce cardiac repair and may also be immunoprivileged (suitable for allogeneic applications). However, it is unclear whether allogeneic MSCs retain their immunoprivilege or functional efficacy late after myocardial implantation. We evaluated the effects of MSC differentiation on the immune characteristics of cells in vitro and in vivo and monitored cardiac function for 6 months after post-myocardial infarction MSC therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research